Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial

Emanuela Marcantoni; Michael S. Garshick; Tamar Schwartz; Nicole Ratnapala; Matthew Cambria; Rebecca Dann; Meagan O'Brien; Adriana Heguy; Jeffrey S. Berger

doi:10.1016/j.jacbts.2022.06.002

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial

Emanuela Marcantoni, Michael S. Garshick, Tamar Schwartz, Nicole Ratnapala, Matthew Cambria, Rebecca Dann, Meagan O'Brien, Adriana Heguy, Jeffrey S. Berger

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted.

Original language	English
Pages (from-to)	1086-1097
Number of pages	12
Journal	JACC: Basic to Translational Science
Volume	7
Issue number	11
DOIs	https://doi.org/10.1016/j.jacbts.2022.06.002
State	Published - Nov 2022
Externally published	Yes

Keywords

HIV
aspirin
clopidogrel
endothelium
platelets

Access to Document

10.1016/j.jacbts.2022.06.002

Cite this

@article{b9575080c4984b0288866536bd8170e7,

title = "Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial",

abstract = "Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted.",

keywords = "HIV, aspirin, clopidogrel, endothelium, platelets",

author = "Emanuela Marcantoni and Garshick, \{Michael S.\} and Tamar Schwartz and Nicole Ratnapala and Matthew Cambria and Rebecca Dann and Meagan O'Brien and Adriana Heguy and Berger, \{Jeffrey S.\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = nov,

doi = "10.1016/j.jacbts.2022.06.002",

language = "English",

volume = "7",

pages = "1086--1097",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV

T2 - A Randomized Controlled Trial

AU - Marcantoni, Emanuela

AU - Garshick, Michael S.

AU - Schwartz, Tamar

AU - Ratnapala, Nicole

AU - Cambria, Matthew

AU - Dann, Rebecca

AU - O'Brien, Meagan

AU - Heguy, Adriana

AU - Berger, Jeffrey S.

PY - 2022/11

Y1 - 2022/11

N2 - Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted.

AB - Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted.

KW - HIV

KW - aspirin

KW - clopidogrel

KW - endothelium

KW - platelets

UR - https://www.scopus.com/pages/publications/85141772782

U2 - 10.1016/j.jacbts.2022.06.002

DO - 10.1016/j.jacbts.2022.06.002

M3 - Article

AN - SCOPUS:85141772782

SN - 2452-302X

VL - 7

SP - 1086

EP - 1097

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 11

ER -

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this